[vc_row][vc_column][vc_column_text]<\/p>\n
\u0645\u0644\u062e\u0635 \u0627\u0644\u0628\u062d\u062b<\/strong><\/p>\n \u03b23<\/sub>-Adrenoceptors mediate several functions in rodents that could be beneficial for the treatment of obesity and type 2 diabetes. This includes promotion of insulin release from the pancreas, cellular glucose uptake, lipolysis, and thermogenesis in brown adipose tissue. In combination, they lead to a reduction of body weight in several rodent models including ob\/ob mice and Zucker diabetic fatty rats. These findings stimulated drug development programs in various pharmaceutical companies, and at least nine \u03b23<\/sub>-adrenoceptor agonists have been tested in clinical trials. However, all of these projects were discontinued due to the lack of clinically relevant changes in body weight. Following a concise historical account of discoveries leading to such drug development programs we discuss species differences that explain why \u03b23<\/sub>-adrenoceptors are not a meaningful drug target for the treatment of obesity and type 2 diabetes in humans.<\/p>\n <\/p>\n \u0643\u064a\u0641\u064a\u0629 \u0627\u0644\u0627\u0633\u062a\u0634\u0647\u0627\u062f \u0644\u0644\u0628\u062d\u062b:<\/strong><\/p>\n Dwaib, H. S., & Michel, M. C. (2023). Is the \u03b23-Adrenoceptor a Valid Target for the Treatment of Obesity and\/or Type 2 Diabetes?.\u00a0Biomolecules<\/em>,\u00a013<\/em>(12), 1714.\u200f<\/p>\n